Allosteric inhibitors of the main protease of SARS-CoV-2

SARS-CoV-2 has raised the alarm to search for effective therapy for this virus. To date several vaccines have been approved but few available drugs reported recently still need approval from FDA. Remdesivir was approved for emergency use only. In this report, the SARS-CoV-2 3CLpro was expressed and...

Descripción completa

Detalles Bibliográficos
Autores principales: Samrat, Subodh Kumar, Xu, Jimin, Xie, Xuping, Gianti, Eleonora, Chen, Haiying, Zou, Jing, Pattis, Jason G., Elokely, Khaled, Lee, Hyun, Li, Zhong, Klein, Michael L., Shi, Pei-Yong, Zhou, Jia, Li, Hongmin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9272661/
https://www.ncbi.nlm.nih.gov/pubmed/35835291
http://dx.doi.org/10.1016/j.antiviral.2022.105381

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9272661/
https://www.ncbi.nlm.nih.gov/pubmed/35835291
http://dx.doi.org/10.1016/j.antiviral.2022.105381

Ejemplares similares